Prenatal tests conducted during pregnancy provide information about the health of the baby by providing information regarding the chromosomal abnormalities. Every year, an estimated 7.9 million children—6% of total births worldwide are born with a serious birth defect of genetic or partially genetic origin. Technological advancements in genomics ensure accuracy of prenatal diagnosis. Further, advancements in screening and diagnosis techniques and devices leads to an easy detection of problems such as neural tube defects, chromosome abnormality, gene mutations, genetic disorders or any birth defects such as cleft palate, trisomies and sickle cell anemia. A large range of prenatal tests are available to evaluate the healthy development of the future baby prior to birth. Non-invasive tests stand as one of the most distinctive technologies impeding the concerns related to genetic diseases. Non-invasive prenatal testing (NIPT), a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cf-DNA) in the maternal plasma is considered as a valuable test for the pregnant women to provide early diagnosis of genetic disorders.

Test providers have pioneered non-invasive prenatal screening by incorporating new scientific advances to offer a state-of-the-art non-invasive prenatal test, backed by the expertise. NIPT can be performed using next generation sequencing (NGS), microarray technology, and polymerase chain reaction technology. Massively parallel sequencing (MPS) method entails breaking down a large sequencing project into smaller ones and sequencing of maternal plasma therefore enables identification of chromosomal origin of each sequenced DNA molecule, fetal and maternal and can detect chromosomal over representation or chromosomal aberrations in fetus.

Increasing developments in the NIPT sector for the launch of new technologies and products having higher detection rates and faster detection for abnormalities have the ability to increase the adoption of NIPT products and services. For instance, in June 2019, Illumina, Inc. (U.S.) launched the VeriSeq NIPT Solution v2, with the ability to screen for a broader range of chromosomal and sub-chromosomal conditions within 10 weeks of gestation with single maternal blood draw. Also, in January 2019, Yourgene Health plc (U.K.) launched the Sage 32 plex test having technology for detection of placental DNA at a faster rate with the reduction in the number of invasive follow-up tests. It also enables to process up to 32 samples in one sequencing run.

The increase in occurrences of chromosomal abnormalities among fetus and advantages provided by the non-invasive methods over invasive ones for their detection leads to the increasing focus in R&D for launch of advanced non-invasive technologies. This would result in the development of new products having lower cost, time, and methodology benefits over the existing products. Thus, development of advanced technologies and NIPT products with advanced features exhibit a rapid growth in non-invasive prenatal testing market, which is expected to grow at a CAGR of 17.1% to reach $13.1 billion by 2027, according to the Meticulous Research®.

Meticulous Research®, can be accessed at @


Tags: non-invasive prenatal testing market Healthcare


Related Reports